Thymosin Alpha-1 vs MOTS-c: Cost and Access Head-to-Head
HealthRX.com
Neither peptide has an approved US product to price
Key numbers
- 1.6 mgZadaxin injection strength; approved only in some other countries, not the USSource: fda.gov, as cited Nov 7, 2026
- 0.5 mg/kg/dayMOTS-c mouse dose by injection; rodent data, not a human doseSource: fda.gov, as cited Nov 7, 2026
- 15 mg/kgMOTS-c dose in a late-life mouse lifespan study; rodent only, not a human doseSource: fda.gov, as cited Nov 7, 2026
- 20%Lower body weight in high-fat-diet mice treated with MOTS-c; animal result onlySource: fda.gov, as cited Nov 7, 2026
At a glance
- US marketed product / None for either peptide
- FDA approval / Neither; MOTS-c is not part of any approved drug [1][2]
- Approved in other countries / Thymosin alpha-1 (Zadaxin) in some, including Italy, India and Hong Kong [2]; FDA found no MOTS-c product authorized by the European Medicines Agency [1]
- Advisory votes / MOTS-c in favour, July 2026 [5]; thymosin alpha-1, 4 yes and 17 no, December 2024 [6]
- FDA list for state-licensed pharmacies and physicians / Neither appears in any of the three categories [7][8]
- FDA list for outsourcing facilities / Thymosin alpha-1 in the nominated-without-adequate-support category; MOTS-c in none [7][8]
- HHS draft peptide policy, October 2026 / Names MOTS-c; does not name thymosin alpha-1 [4]
Is there an approved US product for either peptide?
No. Thymosin alpha-1 has no US marketing application [2], and MOTS-c is not a component of any FDA-approved drug [1]. Compounded drugs are not FDA-approved: FDA does not review their safety, effectiveness or quality before marketing [3]. For MOTS-c, FDA found it marketed on websites and in combinations, and no outsourcing facility reported compounding it from January 2017 to December 2025 [1].
The one finished product is sold abroad. Zadaxin is a 1.6 mg thymalfasin injection approved in some other countries, including Italy, India and Hong Kong, and it is not interchangeable with bulk thymosin alpha-1 powder [2].
Where access actually differs
Thymosin alpha-1 appears in none of the three categories on FDA's list for state-licensed pharmacies and physicians. It sits in category 3 (nominated without adequate support) on the outsourcing facility list. FDA's interim policy of not acting against compounders of certain nominated substances therefore does not reach it [7][8][9]. FDA still posts immunogenicity and characterization concerns for it on its safety-risk page, where it sits in the nominated-but-withdrawn table [10].
MOTS-c is in none of the three categories on either list [7][8][9]. FDA staff proposed in July 2026 that neither its free base nor its acetate be added, citing no human safety or effectiveness data and no animal toxicity studies [1]. The committee voted in favour on July 23, 2026, against staff's recommendation. That is advice only; MOTS-c is not on the list, and adding it takes rulemaking [5][11].
Questions worth asking
The October 2026 HHS draft names MOTS-c only
The draft enforcement-discretion policy was filed October 28, 2026 (Federal Register document 2026-22192; publication scheduled October 30, 2026; comments due two weeks after). It names six peptides (BPC-157, epitalon, KPV, MOTS-c, Semax and TB-500) and covers MOTS-c acetate by subcutaneous or intramuscular injection [11][4]. HHS says it does not intend to take enforcement action against a state-licensed pharmacy, federal facility or licensed physician compounding it where conditions are met. Examples are a single active ingredient, a patient-specific prescription and an FDA-registered manufacturer with a certificate of analysis [4]. The notice says it creates no rights and is not binding on HHS or the public [11]. Thymosin alpha-1 is not among the six [4].
What human data sits behind each
A 2026 Cochrane review of 10 randomized trials and 1349 adults with chronic hepatitis B found possible lower all-cause mortality with thymosin alpha-1 (risk ratio 0.53, 95% CI 0.29 to 0.96; 3 trials, 907 people), but at very low certainty. The reviewers said they are not sure it helps [12].
FDA found no published study in which MOTS-c was given to a human [1]. All MOTS-c pharmacology comes from cells and rodents. In mice on a high-fat diet, MOTS-c treatment produced about 20% lower body weight after 8 weeks at 0.5 mg/kg/day by intraperitoneal injection [1][13]. A late-life schedule of 15 mg/kg three times weekly beginning at 23.5 months increased median lifespan from 912 to 970 days in mice [1][14]. FDA says no dose-response relationships were assessed, and there is no approved or human-tested dose of MOTS-c. The rodent doses cannot be converted into human doses [1].
Check what you know
Question 1 of 4
Score: 0 right, 0 of 4 answered
Frequently asked questions
Is either peptide FDA-approved?
Does the HHS draft make MOTS-c legal to compound?
Is there an approved product I could look up a cost for?
Are these peptides banned in sport?
Reader questions
What people actually ask
Short answers drawn from the sources this article cites.
How much does MOTS-c peptide cost?
No MOTS-c price is established. Neither peptide has an FDA-approved US product, and compounded drugs are not reviewed by FDA for safety, effectiveness or quality before marketing. MOTS-c also has no approved or human-tested dose, so no dose-based cost can be set.
How much does thymosin alpha 1 cost?
No thymosin alpha-1 price is established. It has no US marketing application, so there is no FDA-approved product to price. The one finished product, Zadaxin, is approved only in some other countries, including Italy, India and Hong Kong, and is not interchangeable with bulk thymosin alpha-1 powder.
References
Show all 15 referencesHide references
- U.S. Food and Drug Administration.
- U.S. Food and Drug Administration.
- Human Drug Compounding Laws | FDA.
- Official web page.
- U.S. Food and Drug Administration.
- U.S. Food and Drug Administration.
- U.S. Food and Drug Administration.
- U.S. Food and Drug Administration.
- Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act | FDA.
- Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks | FDA.
- Official web page.
- Naing C, Ni H, Aung HH, Aye SN, Nikolova D, Poovorawan Y, et al. Thymosin-ɑ1 for people with chronic hepatitis B. Cochrane Database Syst Rev. 2026.
- Lee C, Zeng J, Drew BG, Sallam T, Martin-Montalvo A, Wan J, et al. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metab. 2015;21(3):443-54.
- Reynolds JC, Lai RW, Woodhead JST, Joly JH, Mitchell CJ, Cameron-Smith D, et al. MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis. Nat Commun. 2021;12(1):470.
- World Anti-Doping Agency.